Co-Diagnostics’ (CODX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Co-Diagnostics (NASDAQ:CODX) in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.36) EPS.

CODX has been the topic of a number of other research reports. D. Boral Capital restated a “buy” rating and set a $3.00 price objective on shares of Co-Diagnostics in a research report on Tuesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Co-Diagnostics in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded Co-Diagnostics to a “hold” rating in a research note on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Co-Diagnostics presently has an average rating of “Hold” and a consensus target price of $1.83.

Co-Diagnostics Price Performance

Shares of NASDAQ:CODX opened at $0.37 on Monday. Co-Diagnostics has a 1 year low of $0.23 and a 1 year high of $1.55. The company has a market cap of $22.73 million, a P/E ratio of -0.38 and a beta of 0.98. The stock’s fifty day moving average price is $0.40 and its 200-day moving average price is $0.33.

Co-Diagnostics (NASDAQ:CODX) last issued its earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The business had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.30 million. Co-Diagnostics had a negative return on equity of 70.26% and a negative net margin of 6,347.34%. On average, sell-side analysts anticipate that Co-Diagnostics will post -1.22 earnings per share for the current year.

Institutional Investors Weigh In On Co-Diagnostics

An institutional investor recently raised its position in Co-Diagnostics stock. Jane Street Group LLC boosted its position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) by 314.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 166,254 shares of the company’s stock after acquiring an additional 126,105 shares during the period. Jane Street Group LLC owned 0.50% of Co-Diagnostics worth $47,000 at the end of the most recent quarter. Institutional investors and hedge funds own 14.99% of the company’s stock.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.